• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Novo Nordisk A>Novo Nordisk A/S ADR

Novo Nordisk A/S ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Keller Rohrback L.L.P. Files Class-Action Lawsuit Over the Inflated Price of Insulin

    Keller Rohrback L.L.P. Files Class-Action Lawsuit Over the Inflated Price of Insulin

  2. SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Novo Nordisk A/S and Encourages Investors with Losses to Contact the Firm

    SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Novo Nordisk A/S and Encourages Investors with Losses to Contact the Firm

  3. March 13 Deadline Alert: Law Offices of Howard G. Smith Reminds Novo Nordisk A/S Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm

    March 13 Deadline Alert: Law Offices of Howard G. Smith Reminds Novo Nordisk A/S Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm

  4. What We Can Expect From Second-Quarter Earnings

    Morningstar's Heather Brilliant says investors could see a lot of market volatility this upcoming earnings season, but that could make for tremendous buying opportunities of quality names.

  5. Sanofi Shakes Off Patent Losses

    The drugmaker faces less long-term volatility as the focus shifts to steady businesses.

  6. Finding a Margin of Safety in a Fully Valued Market

    These three wide-moat firms are trading at reasonable prices in a market with little breathing room in valuations.

  7. 6 Key Concepts to Stock Investing Defined

    From moats to fair value to stewardship, we explain the key pillars of our approach to equities.

  8. A Preview of the 2014 Morningstar International-Stock Fund Manager of the Year Competition

    These managers are potential contenders for this year's honor.

  9. A Preview of the 2014 Morningstar International-Stock Fund Manager of the Year Competition

    These managers are potential contenders for this year's honor.

  10. Moats and Growth Drivers Look Solid for Post-Split Baxter

    Focus remains on hemophilia competition, but Baxter's comprehensive product portfolios are unmatched.

123

©2017 Morningstar Advisor. All right reserved.